Sneaky Midsole Pen - Trainer Sneaker Touch Up Marker Paint Pen

Product Information

Key message: Training is important as each AAI is given differently, so it is important that you are shown how to use your AAI device. Having a trainer device is a useful tool for practicing how to use your AAI and to teach others how to use it, as this varies from brand to brand.

that they should always carry two in-date auto-injectors with them at all times in case they need to administer a second dose of adrenaline before the arrival of the emergency services; Although the risk of activation failure is now estimated to be higher than was previously reported, most Emerade pens will still activate as intended. Therefore, patients should be advised to retain their unexpired Emerade pens, to avoid being left without access to any adrenaline pens. GPs should also send the attached Patient Letter – Advice for patients with Emerade 300 microgram or Emerade 500 microgram auto-injectors to all patients and carers for information. Actions for healthcare professionals Emerade 500 microgram auto-injectors are not being recalled at present as there are insufficient supplies of alternatives to provide replacements. For all patients currently in possession of Emerade 500 microgram auto-injectors, the advice from MHRA and DHSC remains that the risk to the patient of being left without a pen, and therefore having no adrenaline to administer, is greater than allowing them to keep pens that may not activate, especially if two pens are carried.are aware that this recall also applies to Emerade 150 microgram auto-injectors that are in emergency anaphylaxis kits held by healthcare professionals, such as dental surgery kits etc. schools require separate pens to be kept on the school premises (e.g. in a medical room) in which case prescribers may need to consider issuing more than 2 but no more than four pens per child (of any brand or strength). See further information on the use of pens in school, in the document attached below; It is recommended that you carry two AAIs at all times, this is particularly important for people who have allergic asthma and a food allergy as they are at an increased risk of a severe allergic reaction.1 For Emerade 300 micrograms auto-injectors, the MHRA, in conjunction with the Department of Health & Social Care (DHSC) has established that there are sufficient supplies of alternative auto-injectors to allow a recall to patient level.

General Practitioners (GPs) should send the letter “Advice for patients with an Emerade 300 microgram auto-injector” in the document attached below, to all patients and carers, as appropriate, who have been prescribed Emerade 300 micrograms auto-injectors. Alternatively, you can report via some clinical IT systems (EMIS/SystmOne/Vision/MiDatabank) or by calling the Commission on Human Medicines (CHM) free phone line: 0800-731-6789. call an ambulance (999) immediately after giving the injection and say this is an emergency case of anaphylaxis; General Practitioners (GPs) should send the attached Patient Letter – Advice for patients with an Emerade 150 microgram auto-injector to all patients and carers, as appropriate, who have been prescribed Emerade 150 micrograms auto-injectors. Patients and carers should be told of the important differences between brands of adrenaline pen in how they are used. Pharmacists and pharmacies who receive Emerade 300 microgram auto-injectors from patients should quarantine the pens and return them to the supplier using the supplier’s approved process.inform patients to return Emerade 300 microgram auto-injectors to the pharmacy, when they have obtained two adrenaline auto-injectors in a different brand;

identify patients who have been supplied with Emerade 150 micrograms auto-injectors and ensure they are reviewed to determine whether their adrenaline auto-injector prescription is still appropriate and in line with existing guidance;General Practitioners (GPs) should send the attached letter “Advice for patients who have been prescribed an Emerade 300 microgram auto-injector” in the document attached below, to all patients and carers, as appropriate, who have been prescribed Emerade 300 micrograms auto-injectors. Information in relation to Coronavirus (COVID-19): Emerade 500 microgram auto-injectors are not being recalled. Unless previously actioned during the Emerade 150 microgram recall, GPs should send the attached letter “Advice for patients with Emerade 500 microgram auto-injectors” in the document attached below, to those patients who have been prescribed Emerade 500 microgram auto-injectors, for information. This information is available as separate PDFs in the link for this alert. Actions for healthcare professionals use a second adrenaline auto-injector immediately if an Emerade pen fails to activate despite pressing firmly against the thigh, see Class 2 Medicines Recall: Emerade 150 micrograms solution for injection in pre-filled syringe, PL 33616/0013 (EL(20)A/14) for pictorial guidance; Prescribers should issue no more than 2 adrenaline auto-injectors per patient (of any brand or strength) unless: